BioTuesdays

Tag - Ladenburg Thalmann

Kiora Pharma Logo
Markets

Ladenburg starts Kiora Pharma at buy; PT $6.50

Ladenburg Thalmann initiated coverage of Kiora Pharmaceuticals (NASDAQ:KPRX) with a “buy” rating and price target of $6.50. The stock closed at 13 cents on Aug. 24. Kiora is focused on bringing treatments to the market...

August 25, 2022
Liquidia Logo
Markets

Ladenburg starts Liquidia at buy; PT $15

Ladenburg Thalmann initiated coverage of Liquidia (NASDAQ:LQDA) with a “buy” rating and $15 price target. The stock closed at $5.03 on July 21. Liquidia is a commercial-stage biotechnology company currently focused on...

July 22, 2022
Reneo Therapeutics
Markets

Ladenburg starts Reneo Pharma at buy; PT $45

Ladenburg Thalmann initiated coverage of Reneo Pharmaceuticals (NASDAQ:RPHM) with a “buy” rating and price target of $45. The stock closed at $7.99 on Nov. 19. Reneo’s clinical stage asset, REN001 is in development for...

November 22, 2021
Renovacor New.jpg
Markets

Ladenburg starts Renovacor at buy; PT $22

Ladenburg Thalmann initiated coverage of Renovacor (NASDAQ:RCOR) with a “buy” rating and $22 price target. The stock closed at $7.93 on Oct. 13. Renovacor is a preclinical-stage biotech company focused on developing...

October 14, 2021
Ardelyx-2021
Markets

Ladenburg cuts Ardelyx to neutral from buy

Ladenburg Thalmann downgraded Ardelyx (NASDAQ:ARDX) to “neutral” from “buy” and removed its price target, citing an unproductive post-complete response letter (CRL) Type A meeting with the FDA. The stock closed at $1.09...

October 14, 2021
Aadi-Bioscience
Markets

Ladenburg starts Aadi Bioscience at buy; PT $51

Ladenburg Thalmann launched coverage of Aadi Bioscience (NASDAQ:AADI) with a “buy” rating and price target of $51. The stock closed at $27.96 on Sept. 13. Aadi is a clinical-stage biotechnology company with a single...

September 14, 2021
Tryp_Therapeutics
Markets

Ladenburg starts Tryp Therapeutics at buy; PT $2

Ladenburg Thalmann initiated coverage of Tryp Therapeutics (OTCQB:TRYPF; CSE:TRYP) with a “buy” rating and $2 price target. The stock closed at 37 cents on Aug. 25. Tryp is focused on developing psychedelic...

August 26, 2021
Immutep Logo
Markets

Ladenburg starts Immutep at buy; PT $8.30

Ladenburg Thalmann launched coverage of Immutep of Australia (NASDAQ:IMMP) with a “buy” rating and $8.30. The stock closed at $3.46 0n Aug. 2. Immutep is a clinical-stage immuno-oncology company focused on developing...

August 3, 2021
4D-Pharma-PLC
Markets

Ladenburg starts 4D Pharma at buy; PT $35

Ladenburg Thalmann launched coverage of 4D Pharma PLC (NASDAQ:LBPS) with a “buy” rating and $35 price target. The stock closed at $10.55 on May 12. 4D Pharma is a Leeds, UK-based biotechnology company developing live...

May 13, 2021